It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. These press releases remain on AbbVie's website for historical purposes only. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman … Terms of use. These press releases remain on AbbVie's website for historical purposes only. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Our media library provides you with our official AbbVie media including our logo, building and leaders. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. AbbVie will host a live webcast of … NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. The information in the press releases on these pages was factually accurate on the date of publication. Readers should not rely upon the information in these pages as current or accurate after their publication dates. If you qualify, please. Employing Caribou's CRISPR genome editing platform to engineer CAR-T cells to withstand host immune attack would enable the development of the next-generation of "off-the-shelf" cellular therapies to benefit a broader patient population. Follow @abbvieCanada and @abbvie on Twitter or view careers on our Facebook or LinkedIn page. Site map The information in the press releases on these pages was factually accurate on the date of publication. Privacy policy Before engaging, please read and adhere to our established community guidelines for each channel. These press releases remain on AbbVie's website for historical purposes only. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. Copyright © 2021 AbbVie Inc. North Chicago, Illinois, U.S.A. CoolSculpting® Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas. For more information about AbbVie, please visit us at www.abbvie.com. Subscribe for email alerts Site map | Copyright © 2021 AbbVie Inc. North Chicago, Illinois, U.S.A. AbbVie: Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Looking for more news from AbbVie? Forward Looking Statements for AbbVie Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial … Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. Subscribe for email alerts NORTH CHICAGO, Ill., Feb. 18, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company's Xact device. "We continue to be very well positioned for the long-term. NORTH CHICAGO, Ill., Feb. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. AbbVie assumes no duty to update the information to reflect subsequent developments. AbbVie assumes no duty to update the information to reflect subsequent developments. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 9:40 a.m. Central time. Health Canada Approves VENCLEXTA® (venetoclax) in combination with ... For more information about AbbVie, please visit us at . “We built Abbelfish Machine Translation and AbbVie Search to accelerate and scale the work of our … NORTH CHICAGO, Ill., Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. NORTH CHICAGO, Ill., Feb. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 10 th Annual SVB Leerink Global Healthcare Conference on Friday, February 26. Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics. The MarketWatch News Department was not involved in the creation of this content. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Results from key growth products – including Skyrizi, Rinvoq and Ubrelvy – continue to track ahead of our expectations, our aesthetics portfolio is demonstrating a strong … Find the latest press releases from AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. An archived edition of the session will be available later that day. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Subscription management. View our social media channel guidelines », AbbVie.com YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. Before engaging, please read and adhere to our established community guidelines for each channel. AbbVie assumes no duty to update the information to reflect subsequent developments. PRESS RELEASE . The cash dividend is payable May 14, 2021 to stockholders of record at the close of business on April 15, 2021.. Sign up For more information about AbbVie, please visit us at www.abbvie.com. The information in the press releases on these pages was factually accurate on the date of publication. YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE. IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. AbbVie assumes no duty to update the information to reflect subsequent developments. This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of common stock of Pharmacyclics, nor is it a substitute for the Registration Statement on Form S-4 and tender offer materials that AbbVie filed with the Securities and Exchange Commission (" SEC ") on March 23, 2015, each as amended. -30- RINVOQ may be used as monotherapy or in combination with methotrexate. NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. For more information about AbbVie, please visit us at www.abbvie.com. What’s New: Global biopharmaceutical company AbbVie is leveraging artificial intelligence (AI) and natural language processing (NLP) for research translation, improving collaboration and search capabilities to enable the discovery of new treatments for patients. NORTH CHICAGO, Ill., Feb. 18, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. | AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference, AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products, BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition. Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. NORTH CHICAGO, Ill., Feb. 18, 2021 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.30 per share. Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact. This area is reserved for members of the news media. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives. RINVOQ may be used as monotherapy or in combination with methotrexate. www.abbvie.ca and www.abbvie.com. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. Forward-Looking Statements. These press releases remain on AbbVie's website for historical purposes only. These press releases remain on AbbVie's website for historical purposes only. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. IRVINE, Calif., Jan. 26, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of CoolSculpting® Elite, its next generation fat reduction system with applicators designed to complement the body's natural curves. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. Today, our passionate AbbVie team has approximately 47,000 employees working together to help patients around the world. Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds. This area is reserved for members of the news media. Terms of use. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, … RINVOQ is also indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.1 The EC approval is supported by data from the three pivotal clinical trials SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1, demonstrating RINVOQ's efficacy across multiple measures of disease activity. The "Yes" link below will take you out of the AbbVie family of websites. NORTH CHICAGO, Ill. and BERKELEY, Calif., Feb. 10, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. If you qualify, please. NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. The information in the press releases on these pages was factually accurate on the date of publication. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. The Internet site that you have requested may not be optimized to your screen size. RINVOQ is also indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy. Forward-Looking Statements. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. View our social media channel guidelines », AbbVie.com The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts. Sign up NORTH CHICAGO, Ill., Feb. 10, 2021 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Privacy policy The information in the press releases on these pages was factually accurate on the date of publication. | AbbVie: Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Subscription management. Although allogeneic, "off-the-shelf" CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T cells by the host immune system remains a key challenge to their broader development. AbbVie assumes no duty to update the information to reflect subsequent developments. NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. | AbbVie Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Follow @abbvie on Twitter, Facebook or LinkedIn. The Internet site that you have requested may not be optimized to your screen size. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. See a high-level overview about our business. For media related inquiries, contact the appropriate team member listed here. NORTH CHICAGO, Ill., Oct. 30, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020. It will be accessible through AbbVie's Investor Relations website … AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference, AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products, BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition, AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results, CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite, European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis, Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference, Allergan Aesthetics Enters Into Option to Acquire Cypris Medical, AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call. * 4-6. Follow us on social media. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. | Follow @abbvie on Twitter, Facebook, Instagram, YouTube, and LinkedIn. Since the company's inception in 2013, AbbVie has increased its dividend by 225 percent. | The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie is a research-based global biopharmaceutical company committed to developing innovative, advanced therapies for some of the world’s most complex and critical conditions. The "Yes" link below will take you out of the AbbVie family of websites. NORTH CHICAGO, Ill. , Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021 , before the market opens. AbbVie will host a live webcast of … AbbVie Forward-Looking Statements. CoolSculpting® Elite harnesses proven CoolSculpting® technology to target, freeze, and eliminate treated fat cells.